EZH2 — Enhancer of Zeste Homolog 2

Overview

EZH2 encodes the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), the principal histone H3 lysine 27 (H3K27) methyltransferase in mammalian cells. Through trimethylation of H3K27 (H3K27me3), PRC2 establishes transcriptionally repressive chromatin domains that silence developmental genes, maintain cell identity, and regulate neuronal differentiation. Dysregulation of EZH2-mediated epigenetic silencing is increasingly recognized as a contributor to neurodegenerative disease pathogenesis, particularly in Alzheimer’s disease and Huntington’s disease, where aberrant gene silencing and loss of neuronal identity accelerate neuronal vulnerability.

Gene Structure and Regulation

EZH2 spans approximately 76 kb on chromosome 7q36.1 and contains 20 exons. The gene undergoes alternative splicing, producing short and long isoforms with different catalytic activities. EZH2 expression is high during embryonic development and neural progenitor proliferation but is downregulated in post-mitotic neurons, where EZH1 partially compensates. In aging and neurodegeneration, aberrant re-expression or persistent activity of EZH2 contributes to pathological gene silencing^{1The Polycomb complex PRC2 and its mark in life2011 · Nature · PMID 21116306Open reference}.

Function

PRC2 Catalytic Activity

EZH2 catalyzes mono-, di-, and trimethylation of histone H3K27 through its SET domain. H3K27me3 is the transcriptionally repressive mark that defines Polycomb-silenced chromatin. The PRC2 core complex requires EZH2 together with EED, SUZ12, and RBAP46/48 for catalytic activity. Allosteric activation occurs when H3K27me3 on adjacent nucleosomes stimulates PRC2 via EED’s aromatic cage, enabling spreading of the repressive mark^{2Histone methyltransferase activity of a Drosophila Polycomb group repressor complex2002 · Cell · PMID 12351676Open reference}.

Neuronal Development and Differentiation

EZH2-PRC2 plays essential roles in neural development. It maintains neural stem cell self-renewal by repressing neuronal differentiation genes in progenitors, controls the neuron-glia fate switch through timed EZH2 downregulation, regulates synaptic gene programs including synaptogenesis and plasticity genes, and specifies cortical layer identity during corticogenesis^{3Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex2010 · Proceedings of the National Academy of Sciences · PMID 20802085Open reference}.

Neuronal Survival and Plasticity

In mature neurons, residual PRC2 activity (primarily EZH1-containing) maintains repression of pro-apoptotic genes (BAX, BIM), non-neuronal lineage genes, transposable elements and repetitive sequences, and cell cycle re-entry genes (aberrant activation of which triggers neuronal death)^{4Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration2016 · Nature Neuroscience · PMID 27185944Open reference}.

Disease Associations

Alzheimer’s Disease

Epigenetic dysregulation through EZH2/PRC2 contributes to AD pathogenesis. H3K27me3 accumulates at neuroprotective gene loci (BDNF, synaptic genes) in AD brain. Nuclear tau recruits EZH2 to heterochromatin, and pathological tau disrupts this interaction, causing heterochromatin relaxation and transposable element derepression. Loss of proper PRC2-mediated silencing leads to inappropriate expression of non-neuronal genes, a hallmark of degenerating neurons. EZH2 silences genes that inhibit GSK-3beta, indirectly promoting tau hyperphosphorylation^{5Tau promotes neurodegeneration through global chromatin relaxation2014 · Nature Neuroscience · PMID 25307061Open reference}.

Huntington’s Disease

PRC2 dysfunction is prominent in Huntington’s disease. Polyglutamine-expanded huntingtin interacts with PRC2 components, altering genome-wide H3K27me3 patterns. Medium spiny neurons show the greatest PRC2 redistribution and transcriptional dysregulation. Aberrant H3K27me3 at the BDNF promoter reduces trophic support critical for striatal neuron survival^{6Huntingtin facilitates polycomb repressive complex 22010 · Human Molecular Genetics · PMID 19906967Open reference}.

Weaver Syndrome

Gain-of-function mutations in EZH2 cause Weaver syndrome (OMIM 277590), characterized by intellectual disability, overgrowth, and distinctive facial features, demonstrating that excessive EZH2 activity is also neurotoxic^{7Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability2014 · Nature Genetics · PMID 25232846Open reference}.

Aging and Epigenetic Drift

Age-related changes in EZH2/PRC2 activity contribute to the epigenetic drift hypothesis of neurodegeneration. Progressive loss of H3K27me3 at specific loci with aging, redistribution of PRC2 to inappropriate targets, failure to maintain neuronal identity programs, and increased vulnerability to proteotoxic and oxidative stress are all observed^{8Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease2018 · Nature Neuroscience · PMID 30089914Open reference}.

Expression

EZH2 expression in the brain shows distinct patterns: high in neural progenitors during development, low but functional in mature neurons, moderate in microglia (regulating inflammatory gene programs), and high in oligodendrocyte precursors (essential for differentiation).

Allen Human Brain Atlas: EZH2 expression

Therapeutic Relevance

EZH2 is a druggable target with several approved and investigational inhibitors. Tazemetostat (Tazverik) is an FDA-approved EZH2 inhibitor (for cancer) being investigated for neuroprotective applications. GSK126 and EPZ-6438 are research-grade EZH2 inhibitors showing neuroprotection in HD models. EZH2 activators may restore silencing of pro-death genes in some contexts. Combinatorial epigenetic therapy using EZH2 inhibitors with HDAC inhibitors enables balanced epigenetic modulation.

Molecular Mechanisms

Catalytic Activity

EZH2 catalyzes H3K27 methylation:

• Monomethylation (H3K27me1): Often associated with gene activation

• Trimethylation (H3K27me3): Canonical repressive mark

• Processivity: PRC2 adds multiple marks sequentially

Substrate Specificity

EZH2 shows preference for:

• Unmodified H3K27: Requires unmodified lysine

• Nucleosomal substrates: Works on nucleosomes

• Cooperative activity: Enhanced on chromatin

flowchart TD
    A["PRC2<br/>Complex"] --> B["EZH2<br/>Catalytic"]
    B --> C["H3K27<br/>Methylation"]
    C --> D["Chromatin<br/>Compaction"]
    D --> E["Gene<br/>Silencing"]
    F["Tau/Abeta"] -.-> E

    style A fill:#0e2e10,stroke:#333
    style E fill:#3b1114,stroke:#333

Non-Catalytic Functions

EZH2 has functions independent of methyltransferase activity:

• Scaffold function: Recruiting other proteins

• DNA binding: Direct transcriptional repression

• Protein interactions: Non-enzymatic complexes

Clinical Applications

Cancer Therapy

EZH2 is targeted in cancer:

• Lymphoma: EZH2 mutations in FL and DLBCL

• Prostate cancer: EZH2 overexpression drives metastasis

• Solid tumors: Various EZH2-dependent cancers

Neurodegeneration

Epigenetic therapy approaches:

1. Inhibitor development: Blood-brain barrier penetration

2. Combination therapy: With HDAC or DNMT inhibitors

3. Targeted delivery: Viral vector approaches

4. Biomarkers: H3K27me3 as treatment marker

Summary

Core Functions

EZH2 serves critical epigenetic functions:

1. H3K27 methylation: Catalyzes repressive marks

2. PRC2 component: Part of polycomb complex

3. Gene silencing: Maintains cell identity

4. Development: Essential for neurogenesis

Disease Links

EZH2 dysfunction contributes to:

• ** Alzheimer’s disease**: Epigenetic dysregulation

• Huntington’s disease: Loss of protective silencing

• Cancer: Overexpression or mutations

• Aging: Epigenetic drift

Therapeutic Potential

Targeting EZH2 offers opportunities:

1. Inhibitors: FDA-approved cancer drug

2. Neuroprotection: Potential for neurodegeneration

3. Combination: With other epigenetic drugs

4. Biomarkers: Measurable treatment response

Comparative Biology

Evolution

EZH2 is evolutionarily conserved:

• Drosophila: Original Enhancer of zeste gene

• Zebrafish: Conserved methyltransferase function

• Mouse: Essential for embryonic development

• Human: Highest complexity in regulation

Model Systems

Research uses multiple models:

• Cell lines: Embryonic stem cells, neurons

• Organoids: Brain organoids for development

• Mouse models: Transgenic and knockout

• iPSC: Patient-derived neurons

Species Differences

Key differences across species:

• Expression patterns: Vary by developmental stage

• Isoforms: Alternative splicing

• Regulation: Different control mechanisms

• Disease relevance: Species-specific phenotypes

Research Methods

Detection Methods

Scientists measure EZH2 through:

1. ChIP-seq: Genome-wide binding mapping

2. CUT&RUN: Low-input chromatin profiling

3. ATAC-seq: Chromatin accessibility

4. RNA-seq: Transcriptome analysis

Manipulation Techniques

Functional studies use:

1. CRISPRi: Transcriptional repression

2. siRNA/shRNA: Knockdown approaches

3. Chemical inhibitors: Pharmacological modulation

4. dCas9-KRAB: Epigenetic editing

Readouts

Key experimental endpoints:

1. H3K27me3: Western blot, ELISA

2. Gene expression: qRT-PCR, RNA-seq

3. Cell fate: Differentiation markers

4. Behavior: Learning and memory tests

Future Directions

Emerging Questions

Key questions remain:

1. Cell-type specificity: Which cells to target

2. Timing: When to intervene in disease

3. Specificity: Off-target effects

4. Combination: Optimal drug combinations

Research Priorities

Future studies should focus on:

1. Single-cell epigenomics: Cell-type resolution

2. Spatial profiling: Regional brain mapping

3. Temporal dynamics: Time course analysis

4. Therapeutic delivery: Brain-penetrant drugs

References

See Also

• HDAC1 — histone deacetylase 1

• HDAC2 — histone deacetylase 2

• SIRT1 — NAD-dependent deacetylase

• Chromatin Remodeling in Neurodegeneration

• Huntington’s Disease

• Alzheimer’s Disease

External Links

• NCBI Gene: EZH2

• UniProt: Q15910

• OMIM: 601573

• GeneCards: EZH2